Last reviewed · How we verify
A Single-center, Randomized, Parallel-group, Open-label Pilot Study to Evaluate the Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome
This study aimed to investigate the impact of intensive cholesterol-lowering therapy (including evolocumab), drug treatment for high-risk plaques (Vulnerable plaques) with a high probability of developing acute coronary syndrome. The purpose of this study is to determine the effect of the change in the Lipid core burden index and compare the rate of cardiac events over 12 months following cholesterol therapy.
Details
| Lead sponsor | Korea University Anam Hospital |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 60 |
| Start date | 2021-03-01 |
| Completion | 2024-12 |
Conditions
- Clinical Trial
- Acute Coronary Syndrome
Interventions
- Evolocumab
- NIRS IVUS
Primary outcomes
- Change of 1-year lipid core burden index — 1 year
Countries
South Korea